中国经济网北京1月28日讯圣湘生物(688289.SH)今日收报20.67元，跌幅6.56%。该股目前处于破发状 态。 圣湘生物于2020年8月28日在上交所科创板上市，发行数量为4,000万股，无老股转让，发行价格为50.48 元/股，保荐机构(主承销商)为西部证券（002673）股份有限公司，保荐代表人为李锋、邹扬，联席主承 销商为中信证券股份有限公司。 上市首日，圣湘生物盘中创下上市以来最高价155.55元，为该股上市以来最高价。 圣湘生物募集资金总额为201,920.00万元，募集资金净额为186,926.98万元，较原计划多131,268.98万 元。圣湘生物2020年8月24日披露的招股书显示，公司拟募集资金55,658.00万元，计划用于精准智能分 子诊断系统生产基地项目、研发中心升级建设项目、营销网络及信息化升级建设项目。 圣湘生物上市发行费用为1.50亿元，其中西部证券和中信证券获得保荐及承销费用1.28亿元。 圣湘生物2022年5月26日披露2021年年度权益分派实施公告，根据公司2021年年度股东大会审议通过的 《圣湘生物科技股份有限公司关于2021年度利润分配及资本公积转增股本方案的议 ...

Group 1 - Recent cases of Nipah virus infection have been reported in West Bengal, India, prompting countries like Thailand and Nepal to enhance preventive measures at airports and border checkpoints [1] - The World Health Organization recognizes Nipah virus as a significant global public health challenge due to its long incubation period, ability to infect various animals and humans, and high fatality rate [1] - Several Chinese gene testing companies have quickly responded to the outbreak by developing testing solutions, showcasing their technological capabilities and emergency response abilities [1] Group 2 - Guangzhou Kingmed Diagnostics Group Co., Ltd. has developed a MetaVirus NGS detection service for precise detection and analysis of Nipah virus and other pathogens, providing reports within 19 hours from sample entry [2] - Beijing Bohui Innovation Biotechnology Group has created a Nipah virus nucleic acid testing kit, utilizing the BHQ-Ⅲ automated nucleic acid analysis system to ensure safety and reduce operational risks [2] - Capbio has independently developed a Nipah virus nucleic acid testing kit, focusing on emergency responses to public health events and providing core technical support for global quarantine and disease control monitoring [1][2]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Group 1 - The Nipah virus, classified as a high-priority pathogen by the World Health Organization, has recently caused a new outbreak in West Bengal, India, with a mortality rate ranging from 40% to 75% [1][5] - As of now, there are 5 confirmed cases in West Bengal, with nearly 100 individuals under home quarantine [1] - The outbreak has affected travel plans, with some Chinese tourists canceling trips to Southeast Asia, and health monitoring measures have been intensified at Phuket International Airport for incoming Indian tourists [1][5] Group 2 - Experts indicate that while the risk of the Nipah virus entering China exists, it is currently considered manageable [3][8] - Preventive measures are emphasized, including avoiding contact with bats and pigs, and ensuring food safety [9][8] - Domestic companies have developed testing kits to assist in monitoring and controlling the outbreak, with firms like Shuoshi Biological and Cap Bio providing nucleic acid testing solutions [10][11] Group 3 - The development of targeted drugs and vaccines for the Nipah virus is challenging due to the virus's high danger level and the need for advanced laboratory conditions for research [11] - The sporadic nature of Nipah virus outbreaks complicates the accumulation of clinical trial data necessary for vaccine and drug validation [11] - Potential treatments, such as Favipiravir, have shown some efficacy against the Nipah virus in animal studies and are included in China's treatment guidelines for RNA virus infections [11]

Group 1 - The Nipah virus, classified as a high-priority pathogen by the World Health Organization, has recently caused a new outbreak in eastern India, with a mortality rate ranging from 40% to 75% [1][4] - As of now, West Bengal, India, has reported 5 confirmed cases, with nearly 100 individuals under home quarantine [1][4] - Initial investigations suggest that the first patient, a nurse, may have contracted the virus from contaminated fresh date palm juice [1][4] Group 2 - The outbreak has affected travel plans, with some Chinese tourists canceling trips to Southeast Asia due to concerns over the Nipah virus [3][6] - Health monitoring measures have been intensified at Phuket International Airport for Indian tourists, reflecting the potential impact on tourism [3][4] - Experts indicate that while the risk of the Nipah virus entering China exists, it is currently considered manageable [7][10] Group 3 - Several companies in China have developed domestic testing kits for the Nipah virus, which can assist in monitoring and controlling the outbreak [11] - Companies like Shuoshi Biological and Cap Bio have introduced nucleic acid testing kits to support public health efforts [11] - The development of targeted drugs and vaccines for the Nipah virus is challenging due to the virus's high danger level and the lack of sufficient clinical trial cases [12]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301363 | 美好医疗 | 32.18 | -5.46% | 18.03万 | 5.96 Z | | 301093 | 不是股份 | 79.99 | -5.17% | 9.73万 | · 7.87亿 | | 688351 | 微电生理 | 24.55 | -5.10% | 9.77万 | 2.43 Z | | 688029 | 南微医学 | 81.25 | -4.96% | 4.46万 | 3.64亿 | | 300753 | 爰朋医疗 | 33.75 | -4.74% | 11.59万 | 3.94亿 | | 688068 | 热景生物 | 147.44 | -4.65% | 2.75万 | 4.05 Z | | 688217 | 睿昂基因 | 31.14 | -4.45% | 1.98万 | 6293.79万 | | 300246 | 宝莱特 | 13.79 | -4.44% | 18.01万 | 2.50亿 | | 688393 | 安必 ...

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

达安基因：公司此前表示已有尼帕病毒核酸检测的科研技术储备。 圣湘生物：此前表示推进亨尼帕病毒检测试剂的研发工作。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 据环球时报报道，近日，印度西孟加拉邦暴发尼帕病毒疫情。 另据人民网，鉴于近期尼帕病毒（Nipah Virus）在印度出现传播风险，泰国清迈国际机场已全面升级对 国际入境旅客的健康筛查措施，以加强疫情监测与防控，防范病毒输入风险。 而智通财经介绍，世界卫生组织将尼帕病毒列为一种致命的人畜共患病毒，主要由果蝠携带。该病毒可 通过被污染的食物传播给人类，或直接人传人，死亡率在40%到75%之间。据世卫组织介绍，这种病毒 从感染到出现症状的潜伏期一般为4天至14天，最长可达45天。目前尚无专门针对尼帕病毒的疫苗和有 效疗法。 公司方面，据上市公司互动平台表示， ...

Core Viewpoint - Shengxiang Bio's stock price has shown fluctuations, with a recent decline of 2.04% and a total market value of 11.663 billion yuan, while the company has experienced a year-to-date stock price increase of 6.45% [1] Financial Performance - For the period from January to September 2025, Shengxiang Bio achieved operating revenue of 1.244 billion yuan, representing a year-on-year growth of 20.49%, while the net profit attributable to shareholders decreased by 2.10% to 191 million yuan [2] - Cumulatively, since its A-share listing, Shengxiang Bio has distributed a total of 2.363 billion yuan in dividends, with 967 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Shengxiang Bio increased by 4.17% to 21,600, with an average of 26,772 circulating shares per person, which is a decrease of 4.01% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 9.8053 million shares, a decrease of 1.7872 million shares compared to the previous period, while Hong Kong Central Clearing Limited is a new shareholder with 3.6601 million shares [3] Business Overview - Shengxiang Bio, established on April 23, 2008, and listed on August 28, 2020, focuses on innovative gene technology, encompassing the research, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services [1] - The company's main revenue sources include diagnostic reagents (87.39%), diagnostic instruments (5.71%), testing services (4.55%), and other supplementary services (2.34%) [1]